Publication: Two doses of tranexamic acid reduce blood transfusion in complex spine surgery: A prospective randomized study
Submitted Date
Received Date
Accepted Date
Issued Date
2015-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
15281159
03622436
03622436
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-84953283638
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Spine. Vol.40, No.24 (2015), E1257-E1263
Citation
Manee Raksakietisak, Benjabhorn Sathitkarnmanee, Peeranat Srisaen, Tithiganya Duangrat, Thitima Chinachoti, Pranee Rushatamukayanunt, Nuchanat Sakulpacharoen (2015). Two doses of tranexamic acid reduce blood transfusion in complex spine surgery: A prospective randomized study. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36563.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Two doses of tranexamic acid reduce blood transfusion in complex spine surgery: A prospective randomized study
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
© 2015 Wolters Kluwer Health, Inc. Study Design. Prospective, double-blinded, randomized controlled study. Objective. To determine whether the use of 2 doses of tranexamic acid (TXA) can reduce perioperative blood loss and blood transfusions in low-risk adult patients undergoing complex laminectomy. Summary of Background Data. Complex laminectomy (multilevel laminectomy or laminectomy and instrumentation) is a procedure with a medium risk of blood loss, which may require allogeneic blood transfusion. Previous studies of TXA showed its inconsistent effectiveness in reducing blood loss during spine surgery. The negative results may stem from ineffective use of a single dose of TXA during long and complex operations. Methods. 80 adult (18-65 yr old) patients in Siriraj Hospital, Mahidol University, Thailand were enrolled and allocated into 2 groups (40 patients in each group) by computer-generated randomization. Patients with history of thromboembolic diseases were excluded. Anesthesiologists in charge and patients were blinded. Group I received 0.9% NaCl (NSS) or placebo and group II received 2 doses (15 mg/kg) of TXA. The first dose was administered before anesthesia induction and the second dose, after 3 hours. The assessed outcomes were the amount of perioperative blood loss and the incidence of blood transfusions. Results. 78 patients were analyzed (1 patient in each group was excluded) with 39 patients randomized to each group. There were no differences in patient demographics and pre and postoperative hematocrit levels. The total blood loss in the control group (NSS) was higher [900 (160, 4150) mL] than in the TXA group [600 (200, 4750) mL]. Patients in the control group received more crystalloid, colloid, and packed red blood cell transfusions. Within 24 hours, we observed a 64.6% reduction of blood transfusions (43.5% vs.15.4%, P=0.006). No serious thromboembolic complications occurred. Conclusion. 2 effective doses (15 mg/kg) of TXA can reduce blood loss and transfusions in low-risk adults undergoing complex spine surgery.